Transforming Growth Factor-β Activity Is Potentiated by Heparin Via Dissociation of the Transforming Growth Factor-β/α₂-Macroglobulin Inactive Complex

Timothy A. McCaffrey,* Domenick J. Falcone,‡ Cory E. Brayton,* Lily A. Agarwal,* Frederick G. P. Welt,* and Babette B. Weksler*~

Departments of * Medicine, ‡ Cell Biology and Anatomy, and ~ Pathology, Cornell University Medical College, New York 10021

Abstract. The control of smooth muscle cell (SMC) proliferation is determined by the combined actions of mitogens, such as platelet-derived growth factor, and the opposing action of growth inhibitory agents, such as heparin and transforming growth factor-β (TGF-β). The present studies identify an interaction between heparin and TGF-β in which heparin potentiates the biological action of TGF-β. Using a neutralizing antibody to TGF-β, we observed that the short term antiproliferative effect of heparin depended upon the presence of biologically active TGF-β. This effect was observed in rat and bovine aortic SMC and in CCL64 cells, but not in human saphenous vein SMC. Binding studies demonstrated that the addition of heparin (100 µg/ml) to medium containing 10% plasma-derived serum resulted in a 45% increase in the specific binding of 125I-TGF-β to cells. Likewise, heparin induced a twofold increase in the growth inhibitory action of TGF-β at concentrations of TGF-β near its apparent dissociation constant. Using 125I-labeled TGF-β, we demonstrated that TGF-β complexes with the plasma component α₂-macroglobulin, but not with fibronectin. Heparin increases the electrophoretic mobility of TGF-β apparently by freeing TGF-β from its complex with α₂-macroglobulin. Dextran sulfate, another highly charged antiproliferative molecule, but not chondroitin sulfate or dermatan sulfate, similarly modified TGF-β's mobility. Relatively high, antiproliferative concentrations of heparin (1–100 µg/ml) were required to dissociate the TGF-β/α₂-macroglobulin complex. Thus, it appears that the antiproliferative effect of heparin may be partially attributed to its ability to potentiate the biological activity of TGF-β by dissociating it from α₂-macroglobulin, which normally renders it inactive. We suggest that heparin-like agents may be important regulators of TGF-β's biological activity.

Atherosclerosis is characterized both by proliferative changes in the arterial cells and by biochemical alterations in the extracellular matrix that lead to local occlusive and thrombotic complications. The intimal invasion and proliferation of vascular smooth muscle cells (SMCs)¹ may be a key step in the pathogenesis of atherosclerosis (51). After arterial injury, humans and a variety of other species develop a neointimal vascular lesion composed partially of cells expressing SMC antigens (50, 62). In experimental animals, formation of arteriosclerotic lesions is inhibited by heparin pretreatment (8, 17). This effect of heparin correlates with its ability to inhibit arterial SMC growth in vitro (4, 12, 21, 41, 47), and is distinct from its anticoagulant action (17, 33). The proliferation of other cell types such as fibroblasts, skeletal muscle cells, and tumor cell lines is also inhibited by heparin (10, 24, 28, 33).

The antiproliferative effect of heparin may be of physiologic significance because endothelial cells and postconfluent SMCs produce heparan sulfate proteoglycans that act similarly to heparin (16, 28). Likewise, highly sulfated polysaccharides such as dextran sulfate and mactin can also have antiproliferative effects (33). Other cell-derived glycosaminoglycans, such as chondroitin sulfate and dermatan sulfate, do not exert antiproliferative effects. We have previously reported that heparin corrects the excessive proliferation of SMC derived from aged rats (38). We subsequently observed, as did others (1), that transforming growth factor type beta (TGF-β) was also a potent inhibitor of SMC monolayer growth in vitro. The inhibition induced by TGF-β, however, was observed at almost a 1,000-fold lower molar concentration than has been reported for heparin. To study the mechanism of heparin's antiproliferative effect, we tested the hypothesis that heparin inhibited SMC proliferation by stimulation of TGF-β activity. Even though TGF-β has not been regarded as a heparin-binding growth factor, our findings demonstrate a significant and specific biological interaction between heparin and TGF-β that could contribute to the antiproliferative effect of heparin on vascular SMC as well as other cell types.

1. Abbreviations used in this paper: α₂-M, α₂-macroglobulin; CPC, cetyl-pyridinium chloride; ITS, insulin-transferrin selenium; PDS, plasma-derived bovine serum; SMC, smooth muscle cell; TGF-β, transforming growth factor beta.

© The Rockefeller University Press, 0021-9525/89/07/441/8 $2.00
The Journal of Cell Biology, Volume 109, July 1989 441-448 441
Materials and Methods

Reagents

Human TGF-β (type 1) and PDGF (>99% pure) were purchased from R & D Systems (Minneapolis, MN). FBS was from Flow Laboratories, Inc. (McLean, VA) and plasma-derived bovine serum (PDS) was from Bicmediical Technologies, Inc. (Cambridge, MA). Tritiated thymidine (1 mCi/ml; New England Nuclear, Boston, MA) was used for proliferation assays. α2-Macroglobulin (α2-M) was kindly provided by Dr. Peter Harpel (Cornell University Medical College, New York). Fibronectin was isolated from human serum by published techniques (44). Sodium heparin, dermatan sulfate, and bovine serum albumin were purchased from Sigma Chemical Co. (St. Louis, MO). Chondroitin-6-sulfate was acquired from the Seikagaku Kogyo Co. (Tokyo, Japan) through Miles Laboratories (Naperville, IL). Heparin of low anticoagulant activity (RD7, 7 U/mg) was kindly provided by the Heparin Corp. (Chicago, IL). A highly charged heparin species was recovered from commercially available heparin (Sigma Chemical Co.) by precipitation with cationic cetylpyridinium chloride (CPC). The heparin-CPC complex was partially dissolved with 1.6 M NaCl/0.05 M CPC. Complexes resistant to partial dissolution with 1.6 M NaCl were recovered and dissolved in 2 M NaCl/absolute ethanol (100:15, vol/vol). This heparin fraction (He(1-3)) was purified by several cycles of ethanol precipitation. Unless otherwise specified, heparin used in these experiments is commercially available Sigma heparin.

Cell Culture

Aortic SMCs were obtained from several sources. Bovine aortic SMCs isolated from explants of fresh bovine aortic media were kindly provided by Drs. David Hajjar and Andrew Nicholson (Cornell University Medical College). Rat aortic SMCs were isolated by explant from male Fisher 344 rats 3-4 months of age on a bypass and obtained in accordance with Institutional Review Board approved protocols. Cultured cells were confirmed as SMCs by positive staining for the smooth muscle-specific isoform of actin as recognized by the monoclonal antibody HHF35 (kindly provided by Dr. Allen Gown, University of Washington, Seattle, WA). Cultures of SMCs were used in the second to sixth subpassage. Mink lung epithelial cells (CCL64) were obtained from the American Type Culture Collection (Rockville, MD) in the 60th passage and used in passages 62-68. All cell cultures were maintained in medium 199 (Gibco Laboratories, Grand Island, NY) supplemented with 10% FBS and 50 μg/ml gentamicin sulfate (Gibco Laboratories). Subpassage was achieved with trypsin/EDTA (Flow Laboratories) and a 3:1 split ratio.

Proliferation Assays

The inhibitory effect of heparin on SMC proliferation, and the contribution of TGF-β to that activity, was evaluated by a short term assay of tritiated thymidine incorporation into DNA. This design was used to minimize the possible contributions of any cell-derived inhibitors. SMCs were plated in normal culture medium at 10,000 cells/well in 96-well microtiter plates. After 48 h, the cells were washed once with plain medium 199 and then exposed to the test medium for 14 h before addition of tritiated thymidine (1 μCi/well) for 4 h before harvest. Incorporation of radiolabeled thymidine into DNA was measured by published methods (38). Reported values reflect the average of six replicate wells per experiment. Inhibition of TGF-β activity by specific antibody was achieved by preincubation of the test medium for 1 h with a 1:10 dilution of a 1 mg/ml solution of rabbit anti-human TGF-β (R & D Systems) known to neutralize the biological activity of ~2 ng/ml TGF-β (25). Control groups were incubated with an identical dilution of nonimmune rabbit IgG.

Iodination of TGF-β

TGF-β was iodinated by minor modifications of the chloramine-T method of Ruff and Rizzino (52). Radiolabeled protein normally exhibited a specific activity of 2.5 x 105 cpm/ng protein and migrated as a single DTT-reducible band on SDS-PAGE. Comparison of radiolabeled and unlabeled protein in a growth inhibition assay using CCL64 fibroblasts indicated equivalent biological activities. Inhibition of growth in these studies was determined either by cell counts on a ZBI counter (Coulter Electronics Inc., Hialeah, FL) or by determining DNA content per well by a fluorometric assay in microtiter wells, using a previously published method developed by the authors (37).

Binding Studies

Binding studies were performed essentially as described by Ruff and Rizzino (52). CCL64 cells were plated in normal growth medium in 24-well Costar (Cambridge, MA) plates at a density of 50,000 cells per well for 48 h. The cells were then washed twice with binding buffer (medium 199 plus 0.1% BSA) and iodinated TGF-β was applied to the cells in medium 199 plus 10% PDS. All binding studies were performed after preincubulation of the cells and medium in a 4°C cold room and during gentle agitation on a rotary shaker. Nonspecific binding was assessed by adding 100 ng/ml (>100-fold excess) unlabeled crude TGF-β (20% pure; R & D Systems) at the time the iodinated ligand was added. 2 h later, the cells were washed three times with ice cold binding medium and bound radioactivity was extracted by treating the cells with lysing medium (FBS plus 0.1% Triton X-100 and 10% glycerol). Previous studies have established that this method extracts a large percentage of the cell-bound ligand without releasing the nonspecifically bound counts (52).

Agarose Gel Electrophoresis

The effect of heparin on the electrophoretic mobility of 125I-TGF-β was analyzed by electrophoresis in uncharged, 1% composite agarose-galactomannan gels (Isogel; FMC Bioproducts Corp., Rockland, ME). Gels prepared with 50 mM Tris-acetate buffer (pH 7.0) were run at 150 V/20 mA for ~4 h with cooling. After electrophoresis, sample wells were filled with molten agarose and allowed to cool to prevent the loss of unmerged TGF-β. Proteins were fixed in 10% trichloroacetic acid for 1 h and then washed free of acid and buffer overnight in water. After drying, gels were stained with 0.1% Coomassie brilliant blue R in water/ethanol/acetic acid (65:25:10, vol/vol/vol), then destained, and exposed overnight to Kodak XAR film (Eastman Kodak Co., Rochester, NY) above a Cronex Lightning Plus intensifying screen.

Results

Serum Dependence of the Antiproliferative Effect of Heparin

The antiproliferative effect of heparin on SMCs has been observed under culture conditions that included serum (48). We had previously observed that the proliferation of SMCs derived from young (3-4-mo) rats cultured in 2% PDS and stimulated with PDGF was not inhibited by heparin (38). To
Figure 2. Reversibility of heparin-induced inhibition by antibody to TGF-β. (A) Bovine aortic SMC, (B) rat aortic SMC, and (C) human saphenous vein SMC cells were plated in normal culture medium 48 h before the experiment. The medium was then changed to medium plus 5% FBS with (hatched bars) or without (solid bars) addition of heparin (100 μg/ml) for 18 h before exposure to a 4-h pulse of tritiated thymidine. In the specified groups, antibody to TGF-β or nonimmune rabbit IgG was added at 100 μg/ml to medium plus 5% FBS 1 h previous to adding this to cells. Data points are the mean ± SEM of six replicate wells.

Figure 3. Effects of heparin on the binding of 125I-TGF-β. CCL64 cells were plated in normal culture medium 48 h before the experiment at a density of 25,000 cells/well of a 24-well plate. Binding of 0.1 ng/well (25,000 cpm) 125I-TGF-β was assessed in the presence (nonspecific) or absence (total) of a 100-fold excess of unlabelled TGF-β. Data points represent the mean of quadruplicate determinations in each of three replicate experiments. The cpm's corresponding to the 100% value for each measure of binding are total = 621.2 ± 110 (SEM), nonspecific = 295.8 ± 95, and specific = 325.3 ± 39. Asterisks indicate control (solid bars) and heparin (hatched bars) groups are significantly different, P < 0.05.

The Effects of Antibody to TGF-β on the Growth of SMCs

In parallel studies using rat SMC cultures grown in 2% PDS, it was observed that a neutralizing titer of antibody to TGF-β (100 μg/ml) caused a 36% increase in the rate of DNA synthesis above control (control = 4.576 ± 356 dpm/well; anti-TGF-β = 6.206 ± 482 dpm/well; mean ± SEM, n = 10). In the complete absence of PDS or FBS in the culture media, anti-TGF-β essentially doubled the rate of thymidine incorporation (medium 199 + ITS = 12,367.4 ± 902.3 dpm/well vs. antibody-treated wells = 23,265.2 ± 2,183.9 dpm/well, n = 5). Nonimmune IgG has no effect on the rate of thymidine incorporation in these cells (Fig. 2). Because this antibody-stimulated DNA synthesis was observed in cells that were presumably devoid of exogenous TGF-β, it suggests that these rat SMCs were producing TGF-β which was inhibiting their own growth in an autocrine fashion. The contribution of serum- and cell-derived TGF-β to heparin's antiproliferative effect was examined in the following study.

Reversal of Heparin Inhibition by Antibody to TGF-β

The apparent dependence of heparin's antiproliferative effect on a serum component suggests the possible involvement of a platelet-derived substance, such as TGF-β, that is present in whole blood serum but not in plasma-derived serum. To compare the inhibitory effect of heparin on the proliferation of cells stimulated with serum to the effect of heparin on cells stimulated with PDGF, rat SMCs were changed from normal culture medium to either 2% PDS plus PDGF (10 ng/ml) and insulin-transferrin-selenium (ITS; Sigma Chemical Co.) or to 10% FBS plus ITS. Parallel groups of cells in both media were also treated with heparin (100 μg/ml) for 18 h before a 2-h exposure to tritiated thymidine. As Fig. 1 demonstrates, the PDGF-stimulated rate of DNA synthesis in media containing 2% PDS is not altered by heparin. Whole blood serum–stimulated (10% FBS) DNA synthesis, however, is strongly suppressed by heparin to approximately the level observed with PDGF stimulation. The initial levels of stimulated DNA synthesis differ between the PDGF- and serum-stimulated groups. Nonetheless, the PDGF-treated cells show stimulated DNA synthesis which was not inhibited by heparin to the level of the 2% PDS control.
Figure 4. Effects of heparin on the antiproliferative action of TGF-β. CCL64 cells were plated at 10,000 cells per microtiter well in normal culture medium 48 h before use. The cells were then changed to medium plus 5% PDS and increasing doses of TGF-β with (dashed line) or without (solid line) 100 µg/ml heparin for 18 h before exposure to a 4-h pulse of tritiated thymidine. Each point represents the mean ± SEM, n = 6; asterisks indicate that control and heparin groups are significantly different, P < 0.01.

Effects of Heparin on the Binding of TGF-β

Having demonstrated that heparin loses its short term antiproliferative effect in the absence of biologically active TGF-β, we addressed the possibility that heparin potentiates the activity of TGF-β by increasing the specific binding of TGF-β to cells. This possibility was examined by determining if heparin altered specific binding of radiolabeled TGF-β to cells under conditions similar to those of the growth inhibition assay. We chose CCL64 cells for this assay because of their sensitivity to the antiproliferative action of TGF-β and their ease of handling. Scatchard analysis of the binding of radiolabeled TGF-β to CCL64 cells indicated the presence of a very high affinity, low capacity binding site with an apparent Kd of 8.3 µM (not shown). We chose a saturating concentration of TGF-β (9.8 µM, 25,000 cpm/well), near the apparent dissociation constant, to examine the effects of heparin on TGF-β binding.

To approximate cell culture conditions, the binding studies were conducted in the presence of 10% PDS with or without the addition of heparin (100 µg/ml). Whole blood serum could not be used in these studies because of the confounding effects of unlabeled serum TGF-β. Preliminary experiments (not shown) indicated that the presence of 10% PDS or 100 µg/ml of α2-M reduced both total and specific binding of [3H]-TGF-β to these cells, consistent with previous reports (42). Heparin partially reversed the effect of PDS, increasing the specific binding of TGF-β to the cell monolayer (Fig. 3). Addition of heparin to the binding medium increased specific binding in two ways: (a) reducing nonspecific binding (binding in the presence of a >100-fold excess of cold competitor) to 86% of the level observed in untreated wells (t[13] = 3.3, P = 0.006); and (b) increasing the total binding of TGF-β to 21% above untreated wells (t[13] = 2.74, P = 0.017). The net effect of these two factors is to increase specific binding of TGF-β to cells by 46% above that observed in the absence of heparin (t[13] = 3.3, P = 0.006). This heparin-stimulated binding was not observed in two studies (not shown) in which only 1% BSA was used as the binding medium, but was observed when 10% PDS was used. Heparin-stimulated binding is observed when binding is performed either at 4°C, as described above, or at 37°C (data not shown) which, combined with the previous evidence, implies that heparin does not affect the levels of the TGF-β receptor(s). However, the presence of a certain type of receptor may be required because saphenous vein SMCs did not show heparin-sensitive binding of TGF-β, an effect consistent with our finding that anti-TGF-β does not reverse heparin's inhibitory effect on these cells.

Effect of Heparin on the Biological Action of TGF-β

The fact that heparin potentiated the specific binding of TGF-β in serum or plasma, 125I-TGF-β in 1% carrier BSA was mixed with medium 199 and 10% PDS or 10% whole-blood FBS in the presence or absence of 100 µg/ml heparin and electrophoresed in 1% agarose–galactomannan gel under nondenaturing and nonreducing conditions. The gel was fixed and then autoradiographically exposed overnight. The arrow indicates the migration of the BSA vehicle as determined by Coomassie staining.

Figure 5. Effect of heparin on the electrophoretic mobility of TGF-β in serum or plasma. 125I-TGF-β in 1% carrier BSA was mixed with medium 199 and 10% PDS or 10% whole-blood FBS in the presence or absence of 100 µg/ml heparin and electrophoresed in 1% agarose–galactomannan gel under nondenaturing and nonreducing conditions. The gel was fixed and then autoradiographically exposed overnight. The arrow indicates the migration of the BSA vehicle as determined by Coomassie staining.
β suggested that heparin might also potentiate the biological action of TGF-β. To assess this possibility, the antiproliferative effect of TGF-β was measured in the presence or absence of heparin (100 μg/ml). In cells plated in 10% FBS and then changed to 5% PDS, heparin alone had a significant inhibitory effect on the baseline rate of thymidine incorporation (no heparin or TGF-β [control] = 7,727 ± 447 dpm/well; with heparin = 3,581 ± 443 dpm/well; mean ± SEM, n = 6). To evaluate the effect of each concentration of TGF-β as a percent inhibition relative to its own control or the heparin baseline value just mentioned. As Fig. 4 demonstrates, heparin increased the inhibitory effect of the lowest tested concentrations of TGF-β without substantially altering the maximal inhibitory effect. The inhibitory effect of 50 pg/ml TGF-β, for instance, was increased twofold in the presence of heparin (P < 0.01). Thus, at low concentrations of TGF-β, heparin potentiates its antiproliferative effect.

**Effect of Heparin on the TGF-β/α2-M Complex**

The results of the previous experiments suggested that heparin exerts an antiproliferative effect that correlates with its ability to potentiate the binding and biological action of TGF-β. Platelet-derived or cell-secreted TGF-β that is not receptor bound is rapidly complexed with α2-M, greatly reducing its biological activity (42). Other reports suggest that TGF-β also complexes with fibronectin in plasma (15). We examined the possibility that heparin binds to the inactive TGF-β/α2-M complex in plasma or serum and induces a conformational change or dissociation that exposes the active site of TGF-β to cell surface receptors.

We examined this hypothesis by adding 125I-TGF-β to plasma or serum and determining the ability of heparin to modify the electrophoretic mobility of the complex. Fig. 6 presents the autoradiograph of radiolabeled TGF-β complexed to plasma or serum components and analyzed by nondenaturing 1% agarose gel electrophoresis. Under these conditions, TGF-β that is either free or is complexed to an uncharged protein does not enter the gel, due to its weak cationic nature (23). Migration of TGF-β into the gel is dependent upon formation of a complex with a charged protein and is largely independent of the molecular weight of the complex. Complexes formed in the presence of either FBS or PDS appear to be modified by the addition of heparin at antiproliferative doses as indicated by the increased cathodic migration of the radiolabeled TGF-β (Fig. 5). This suggests that heparin binds directly to TGF-β or to a protein complex containing TGF-β.

As shown in Fig. 6, the addition of heparin to 125I-TGF-β increases the migration of TGF-β into the gel. This strongly suggests that there is a direct interaction between TGF-β and heparin. However, the possibility remains that TGF-β is complexed to a trace contaminant in the albumin carrier which is affected by heparin. Also, as shown in Fig. 6, TGF-β forms a complex with purified α2-M. The addition of heparin to TGF-β/α2-M complexes resulted in the enhanced migration of a large fraction of the radiolabeled TGF-β that was previously comigrating with α2-M. When TGF-β was added to fibronectin, we did not observe the same degree of complex formation that we observed with α2-M. The addition of heparin, however, created the same highly anionic band that was observed when heparin was added to TGF-β alone or in combination with α2-M. Densitometric analysis of the Coomassie-stained gel indicated that heparin did not shift the α2-M band. In contrast, fibronectin's mobility was significantly enhanced by heparin, consistent with previous reports (14). However, in the presence of heparin the radiolabeled TGF-β did not comigrate with fibronectin/heparin complexes. These data suggest that heparin binds to TGF-β and thereby dissociates the TGF-β/α2-M complex.

As shown in Fig. 7, the dissociation of the TGF-β/α2-M complex was observed with heparin and dextran sulfate, both of which are antiproliferative (33). RD7, a heparin with low anticoagulant activity but some antiproliferative activity (data not shown), weakly dissociated the TGF-β/α2-M complex. Chondroitin sulfate and dermatan sulfate, which are not antiproliferative (17), do not modify TGF-β/α2-macro-globulin complexes (Fig. 7). To minimize the possible contribution of any trace contaminants in commercial heparin preparations, we used a highly purified heparin to determine the dose–response characteristics of this interaction. As demonstrated in Fig. 8, the dissociation of the TGF-β/α2-M complex by heparin requires an excess of highly purified heparin (HEP1,3) as determined by increasing the concentration of heparin (1 ng/ml to 100 μg/ml) relative to fixed concentrations of 125I-TGF-β (20 ng/ml) and α2-M (100 μg/ml). As the concentration of heparin is increased, the electrophoretic mobility of 125I-TGF-β shows a marked cathodic shift, while the position of the α2-M on the Coomassie-stained gel was unchanged. Thus, the concentrations of heparin sufficient to free 125I-TGF-β from α2-M are quite similar to the antiproliferative concentrations of heparin reported by several laboratories (10, 12, 22, 24, 38, 47).

**Discussion**

TGF-β is a widely expressed and pluripotent growth factor. Platelets contain, and upon activation release, a high molecular weight, latent form of TGF-β (67) in quantities sufficient
heparin may have important biochemical and physiological
effects and heparin-binding growth factor, our experiments indicate that
heparin binds to the TGF-β/α2-M complex with TX2-M.

Activational mechanism is uncertain, it seems likely that the
putative precursor polypeptide (39, 67). While the precise
activation mechanism is uncertain, it seems likely that the
complex is proteolytically activated by a plasmin-like enzyme to form a 26-kD biologically active molecule (34). Ac-
tive TGF-β is rapidly bound to α2-M (23), presumably serving as a clearance mechanism (9). Thus, TGF-β may exist in
two distinct, biologically inactive forms: the original latent
complex with its precursor and a second clearance complex with α2-M.

Although TGF-β has not previously been considered a
heparin-binding growth factor, our experiments indicate that
heparin may have important biochemical and physiological
interactions with this potent growth and metabolic regulator.
Because heparin is known to interact with acidic fibroblast
growth factor (aFGF, also known as heparin-binding growth
factor-1) to potentiate its mitogenic effect on endothelial cells
(61), an analogous interaction between heparin and TGF-β is
possible. While it has recently been shown that TGF-β binds to
heparin-Sepharose with greater affinity than does PDGF
(25, 45), the physiological significance for this interaction
was not clear. Our studies strongly suggest that at least one
of the growth inhibitory actions of heparin is to potentiate the
receptor binding and anti-proliferative effect of TGF-β via
dissociation of the α2-M complex. The evidence supporting
this interaction is derived from several observations.

First, heparin is a much less effective inhibitor of cell
growth in the absence of serum derived from whole blood,
which contains both PDGF and TGF-β complexed to protein
macromolecules. Initially this observation seemed to conflict
with the findings of Reilly and co-workers (47) who reported
that heparin did inhibit PDGF-stimulated growth. However,
closer examination of the reported methods indicated that
5% calf serum, and thus TGF-β, was present in the PDGF-
supplemented medium. Heparin has been reported to inhibit
SMC proliferation in culture conditions using serum de-
pleted of PDGF by heparin-Sepharose chromatography (4,
47). Although these reports have been interpreted as evidence
that heparin does not interact with a serum factor to cause
growth inhibition, our results indicate that an interaction be-
tween α2-M, which is not removed from serum by heparin-
Sepharose, and TGF-β, which is only partially removed by
heparin-Sepharose (25) and could be supplied by the cul-
tured cells, is still a plausible mechanism for heparin's an-
ti-proliferative effect in this particular setting.

The contribution of TGF-β to heparin's anti-proliferative
effect is further supported by the fact that in the presence of
a neutralizing antibody to TGF-β, heparin did not inhibit
SMC proliferation. That TGF-β present in serum inhibits
SMC growth can be strongly inferred from the substantial in-
crease in DNA synthesis in cells treated with antibody to
TGF-β. This "disinhibition" is attributable to the neutraliza-
tion of TGF-β present in serum. A similar stimulatory effect
of anti-TGF-β is also observed in serum-free cultures of
SMC, suggesting that SMCs produce TGF-β that regulates
their own growth. This has not been previously reported for

Figure 7. Specificity of heparin for the TGF-β/α2-M complex. Agarose gel electrophoresis and autoradiography performed as in
Fig. 5. Purified α2-M (α2M) (100 μg/ml) and 125I-TGF-β were mixed with or without 100 μg/ml of heparin (Hep), dextran sulfate
(DS), chondroitin-6-sulfate (CS), dermatan sulfate (DMS), or RD7, a heparin with antiproliferative but low anticoagulant activity. All polysaccharides were used at 100 μg/ml.

Figure 8. Effect of increasing heparin concentrations on complex formation. Agarose gel electrophoresis as in Figs. 5–7 showing the
requirement of a >50-fold molar excess of purified heparin (HepA) to TGF-β (20 ng/ml) is necessary to cause dissociation of the
α2-M/125I-TGF-β complex. α2-M was present in all lanes at a concentration of 100 μg/ml.
SMCs though it is known that other cell types produce TGF-β in an autocrine fashion (25). The failure of heparin to inhibit DNA synthesis in the absence of functional TGF-β implies that heparin might facilitate the interaction of TGF-β with its receptor.

To test that possibility, it was necessary to examine the cell surface binding of TGF-β in the presence and absence of heparin. At concentrations of TGF-β near its apparent dissociation constant, heparin increased the specific binding of TGF-β by ~50% above untreated control wells. Part of this effect was to reduce nonspecific binding, suggesting that part of TGF-β’s binding to cells is via a heparin-sensitive site. This is consistent with the recent report that the high molecular weight receptor for TGF-β is a glycosaminoglycan and that heparanase digestion reduces TGF-β binding to the cells by ~20% (54). Consistent with the increased binding of TGF-β, heparin also potentiated the growth inhibitory action of very low concentrations of TGF-β. Taken together, this seems reasonable to hypothesize that heparin increases the availability of TGF-β to its receptor, and thereby potentiates the antiproliferative effect of TGF-β on these cell types.

One mechanism by which heparin could influence the binding and action of TGF-β would be for heparin to bind to the TGF-β complex that is formed in serum or plasma and render free TGF-β. It is has been established that TGF-β binds to α2-M in plasma (23) and is less biologically active when so bound (42). Because TGF-β, but not α2-M, binds heparin, we were not surprised to find that the electrophoretic mobility of TGF-β bound to plasma proteins was substantially altered by the presence of highly electronegative heparin. This heparin/TGF-β interaction exhibited glycosaminoglycan specificity and dose-response characteristics that parallel those described for heparin’s antiproliferative effect. Based on these results, we propose that heparin frees TGF-β from its binding site to α2-M and forms a stable, electronegative complex that is receptor competent. The large molar excess of heparin necessary to achieve this dissociation suggests that either a small subtype of heparin is effective or that heparin has a lower affinity than α2-M for TGF-β.

An interaction between TGF-β and heparin would have broad physiological implications because both TGF-β and heparin-like glycosaminoglycans are produced in substantial quantities by a variety of cell types. Endothelial cells, for instance, produce heparan sulfate species (69), as well as relatively high levels of latent TGF-β, implying that the combined effect of these factors may help to maintain cell cycle quiescence in the underlying SMC. Furthermore, because TGF-β is known to increase the synthesis of matrix proteoglycans, there is the potential for feedforward/feedback mechanisms to regulate the extracellular activity of TGF-β during wound healing, angiogenesis, and potentially atherosclerosis. It is interesting to speculate that a TGF-β/heparin interaction may also be involved in the regulation of bone integrity. Long term heparin therapy is often accompanied by osteoporosis (53), and TGF-β is already well recognized as having important functions in the proliferation and metabolism of osteoclasts and osteoblasts (6, 44, 60). In conclusion, our results suggest the possibility that the interaction of heparin, or possibly heparan sulfate proteoglycans, and TGF-β has important regulatory functions in both normal and pathological conditions of the vasculature. Further investigation of this interaction will allow a better understanding of the factors that govern the balance of growth stimulatory and growth inhibitory signals acting on the mammalian cell.

This work was supported in part by a grant from the American Federation for Aging Research to T. McCaffrey, a National Institutes of Health (NIH) Research Career Development Award (HL01962) to D. Falcone, and NIH research grants HL35724 and HL18828 to B. Weksler.

Received for publication 3 November 1988 and in revised form 17 January 1989.

References

1. Assoian, R. K., and M. B. Sporn. 1986. Type β transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J. Cell. Biol. 102:1217–1223.

2. Baird, A., and T. Durkin. 1986. Inhibition of endothelial cell proliferation by type β-transforming growth factor: interactions with acidic and basic fibroblast growth factors. Biochem. Biophys. Res. Commun. 138:476–482.

3. Bassols, A., and J. Massague. 1986. Transforming growth factor β regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J. Biol. Chem. 263:3039–3045.

4. Benitz, W. E., D. S. Lessler, J. D. Coughon, and M. Bernfield. 1986. Heparin inhibits proliferation of fetal vascular smooth muscle cells in the absence of platelet derived growth factor. J. Cell. Physiol. 127:1–7.

5. Chen, J., H. Hoshi, and W. L. McKeehan. 1987. Transforming growth factor type β specifically stimulates synthesis of proteoglycan in human arterial smooth muscle cells: Proc. Natl. Acad. Sci. USA. 84:5257–5261.

6. Chenu, C., J. Pleischatter, G. R. Mundy, and G. D. Rodman. 1988. Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc. Natl. Acad. Sci. USA. 85:5653–5667.

7. Clark, W. C., and J. Bressler. 1988. Transforming growth factor-β-like activity in tumors of the central nervous system. J. Neurosurg. 68:920–924.

8. Clowes, A., and M. Karnovsky. 1977. Suppression of smooth muscle cell proliferation in injured arteries. Nature (Lond.). 265:625–626.

9. Coffey, R. J., L. J. Kost, R. M. Lyons, H. L. Moses, and N. F. LaRusso. 1987. Hepatic processing of transforming growth factor β in the rat. J. Clin. Invest. 80:750–757.

10. Del Vecchio, P. J., R. Bizios, L. A. Holleran, T. K. Judge, and G. L. Pinto. 1988. Inhibition of human scleral fibroblast proliferation with heparin. Invest. Ophthalmol. & Visual Sci. 29:1272–1276.

11. Ewton, D. Z., G. Spizz, E. N. Olson, and J. R. Florini. 1988. Decrease in transforming growth factor-β binding and action during differentiation in muscle cells. J. Biol. Chem. 263:4029–4032.

12. Egger, G., G. K. Hanson, P. Ottersen, B. Dahloid, and G. Bondjers. 1988. Human arterial smooth muscle cells in culture: effects of platelet-derived growth factor and heparin on growth in vitro. Exp. Cell Res. 176:519–335.

13. Falanga, V., S. I. Tieg, S. P. Alstadd, A. B. Roberts, and M. B. Sporn. 1987. Transforming growth factor-beta selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. J. Invest. Dermatol. 89:100–104.

14. Falzone, D. J., and B. G. Lisbury. 1988. Fibromectin stimulates macrophage uptake of low density lipoprotein-heparin-collagen complexes. Arteriosclerosis. 8:263–273.

15. Fava, R. A., and D. B. McClure. 1987. Fibromectin-associated transforming growth factor. J. Cell. Physiol. 131:184–189.

16. Fritz, L., C. F. Reilly, and R. D. Rosenberg. 1985. An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J. Cell. Biol. 100:1041–1049.

17. Guyton, J., R. Rosenberg, A. Clowes, and M. Karnovsky. 1980. Inhibition of rat arterial smooth muscle cell proliferation by heparin. I. In vivo studies with anticoagulant and non-anticoagulant heparin. Circ. Res. 46:625–634.

18. Deleted in proof.

19. Heimark, R. L., D. R. Twardziak, and S. M. Schwartz. 1986. Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science (Wash. DC). 233:1078–1080.

20. Hill, D. J., A. J. Strain, S. F. Elstow, I. Swenne, and R. D. G. Milner. 1986. Bi-functional action of transforming growth factor-β on DNA synthesis in early passage human fetal fibroblasts. J. Cell. Physiol. 128:322–328.

21. Hover, R., R. Rosenberg, W. Haering, and M. Karnovsky. 1980. Inhibition of rat smooth muscle cell proliferation by heparin II. In vitro studies. Circ. Res. 47:578–583.

22. Hoshi, H., M. Kan, J. K. Chen, and W. L. McKeehan. 1988. Comparative endocrinology-paracrinology-autocrinology of human adult large vessel endothelial and smooth muscle cells. In Vitro Cell. & Dev. Biol.
23. Huang, S., F. O'Grady, and J. Huang. 1988. Human transforming growth factor-beta/alpha-2-macroglobulin complex is a latent form of transforming growth factor-beta. J. Biol. Chem. 263:1535-1541.

24. Kardami, E., D. Spector, and R. C. Strohman. 1988. Heparin inhibits skeletal muscle growth in vitro. Dev. Biol. 126:19-28.

25. Keski-Oja, J., R. M. Lyons, and H. L. Moses. 1987. Immunodetection and modulation of cellular growth with antibodies against native transforming growth factor-β. Cancer Res. 47:6451-6458.

26. Kimchi, A., X. F. Wang, R. A. Weinberg, S. Cheifetz, and J. Massague. 1988. Absence of TGF-β receptors and growth inhibitory responses in retinoblastoma cells. Science (Wash. DC.) 240:196-198.

27. Kimura, A., O. Katoh, and A. Kuramoto. 1988. Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor-β on the growth of human narrow fibroblasts. Br. J. Haematol. 69:9-12.

28. Klebe, R. J., L. V. Escobedo, K. L. Bentley, and L. K. Thompson. 1986. Regulation of cell motility, morphology, and growth by sulfated glycosaminoglycans. Cell Motil. Cytoskeleton. 6:273-281.

29. Krycve-Martinerie, C., D. A. Lawrence, J. Crochet, P. Jullien, and P. Vigier. 1985. Further study of β-TGFs released by virally transformed and non-transformed cells. Int. J. Cancer. 35:553-558.

30. Lawrence, D. A., R. Pircher, and P. Jullien. 1985. Conversion of a high molecular weight active β-TGF under acidic conditions. Biochim. Biophys. Res. Comm. 133:1026-1034.

31. Lawrence, D. A., R. Pircher, C. Kryceve-Martineri, and P. Jullien. 1984. Normal embryo fibroblasts release transforming growth factors in a latent form. J. Cell. Physiol. 121:184-188.

32. Leof, E. B., J. A. Proper, A. S. Goustin, G. D. Shipley, P. E. DiCorleto, and H. L. Moses. 1986. Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor-β: a proposed model for indirect mitogenesis involving autocrine activity. Proc. Natl. Acad. Sci. USA. 83:2453-2457.

33. Lipman, M. M., and M. B. Mathews. 1977. Heparin: varying effects on cell proliferation in vitro and in vivo and lack of correlation with anticoagulant activity. Fed. Proc. 36:55-59.

34. Lyons, R. M., J. Keski-Oja, and H. L. Moses. 1988. Proteolytic activation of latent transforming growth factor β from fibroblast-conditioned medium. J. Cell. Biol. 106:1559-1565.

35. Majack, R. A. 1987. Beta-type transforming growth factor specific organizers behavior in vascular smooth muscle cell cultures. J. Cell. Biol. 105:465-471.

36. Massague, J., and B. Like. 1985. Cellular receptors for type β transforming growth factor. J. Biol. Chem. 260:2636-2645.

37. McCaffrey, T. A., L. A. Agarwal, and B. B. Weksler. 1988. A rapid fluorometric DNA assay for the measurement of cell density and proliferation in vitro. In Vitro Cell. & Dev. Biol. 24:247-252.

38. McCaffrey, T. A., A. C. Nicholson, P. E. Szabo, M. E. Weksler, and B. B. Weksler. 1988. Aging and arteriosclerosis: the increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity. J. Exp. Med. 163:163-174.

39. Miyazono, K., U. Hellman, C. Wernstedt, and C. Heldin. 1988. Latent high molecular weight complex of transforming growth factor-beta 1. J. Biol. Chem. 263:6407-6415.

40. Nilsson, J., T. Kiaszak, C. H. Heldin, and J. Thyberg. 1983. Demonstration of stimulatory effects of platelet-derived growth factor on cultivated rat arterial smooth muscle cells. Exp. Cell Res. 145:231-237.

41. Nilsson, J., T. Kiaszak, J. Thyberg, and A. Watterson. 1983. Cell surface complex formation and growth regulation in cultivated arterial smooth muscle cells. J. Cell. Sci. 64:107-121.

42. O'Connor-McCourt, M. D., and L. M. Wakefield. 1987. Latent transforming growth factor β in serum. J. Biol. Chem. 262:14090-14099.

43. Pecnny, D. W., and T. G. Wickremasinghe. 1988. Transforming growth factor β increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc. Natl. Acad. Sci. USA. 85:11098-11102.

44. Pfeilschifter, J., S. M. Seyedin, and G. R. Mundy. 1987. Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures. J. Clin. Invest. 82:680-685.

45. Pappo, D. A., D. Mark, M. J. Banda, and Z. Werb. 1988. Wound macromolecules express TGF-β and other growth factors in vivo: analysis by mRNA phenotyping. Science (Wash. DC). 241:708-712.

46. Redin, F., P. Galera, A. Mauviel, G. Loyau, and J. P. Pujol. 1988. Transforming growth factor β stimulates collagen and glycosaminoglycan biosynthesis in cultured rabbit articular chondrocytes. FERS (Fed. Eur. Biochem. Soc.) Lett. 234:172-176.

47. Reilly, C. F., L. Fritze, and R. D. Rosenberg. 1986. Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J. Cell. Physiol. 129:11-19.

48. Reilly, C. F., L. M. S. Fritze, and R. D. Rosenberg. 1987. Antiproliferative effects of heparin on vascular smooth muscle cells are reversed by epidermal growth factor. J. Cell. Physiol. 131:149-157.

49. Rizzino, A. 1987. Appearance of high affinity receptors for type β transforming growth factor during differentiation of murine embryonic carcinoma cells. Cancer Res. 47:4386-4390.

50. Ross, R. 1985. Platelets and atherosclerosis. J. Clin. Invest. 76:309-320.